Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial

Lancet

Volumn 362, Issue 9392, 2003, Pages 1255-1260

  Henke, Michael ^a   Laszig, Roland ^b   Rübe, Christian ^b   Schäfer, Ulrich ^b   Haase, Klaus Dieter ^c   Schilcher, Burkhard ^c   Mose, Stephan ^d   Beer, Karl T ^e   Burger, Ulrich ^f   Dougherty, Chris ^f   Frommhold, Hermann ^a  

^a Abt Strahlenheilkunde R   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FERROUS GLUCONATE; HEMOGLOBIN; IRON; IRON SACCHARATE; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD DISEASE; BRAIN STEM INFARCTION; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; FEMALE; HEAD AND NECK CARCINOMA; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; HYPOPHARYNX CARCINOMA; INFECTION; LARYNX CARCINOMA; LARYNX EDEMA; LEG THROMBOSIS; LUNG EMBOLISM; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MOUTH CARCINOMA; MULTICENTER STUDY; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; THORAX DISEASE; TREATMENT OUTCOME; VASCULAR DISEASE; VEIN THROMBOSIS;

EID: 0142186283     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14567-9     Document Type: Article

References (36)

1. Grau C., Overgaard J. Significance of hemoglobin concentration for treatment outcome. 2000;Springer, New York.
2. Henke M., Momm F., Guttenberger R. Erythropoietin for patients undergoing radiotherapy: the Freiburg experience. 1999;Wissenschaftliche Verlagsgesellschaft, Stuttgart.
3. Oster W., Herrmann F., Gamm H., et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol. 8:1990;956-962.
4. Ludwig H., Fritz E., Kotzmann H., Hocker P., Gisslinger H., Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 322:1990;1693-1699.
5. Lavey R.S., Dempsey W.H. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys. 27:1993;1147-1152.
6. Abels R.I. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol. 87:(suppl 1):1992;4-11.
7. Case D.C. Jr, Bukowski R.M., Carey R.W., et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 85:1993;801-806.
8. Thews O., Koenig R., Kelleher D.K., Kutzner J., Vaupel P. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer. 78:1998;752-756.
9. Silver D.F., Piver M.S. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol. 73:1999;280-284.
10. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys. 50:2001;705-715.
11. Littlewood T.J. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol. 28:(suppl 8):2001;49-53.
12. Cox D.R. Regression models and life table. J R Stat Soc B. 34:1972;187-220.
13. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 54:1958;457-481.
14. Yu L., Vikram B., Malamud S., Yudelman I., Nussbaum M., Beattie E. Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update. Cancer Invest. 13:1995;567-572.
15. Overgaard J., Hansen H.S., Jorgensen K., Hjelm Hansen M. Primary radiotherapy of larynx and pharynx carcinoma - an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys. 12:1986;515-521.
16. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 338:1998;1798-1804.
17. Frommhold H., Guttenberger R., Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy: the Freiburg experience. Strahlenther Onkol. 174:(suppl 4):1998;31-34.
18. Vigario G., Kurohara S.S., George F.W. 3rd. Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. Radiology. 106:1973;649-652.
19. Guttenberger R., Lutterbach J., Roth A., et al. Hemoglobin levels predict local regional control after postoperative radiotherapy for advanced head and neck cancer. Eur J Cancer. 33:(suppl):1997;102-103.
20. Becker A., Stadler P., Lavey R.S., et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 46:2000;459-466.
21. 2 tension measurements. Cancer Res. 51:1991;3316-3322.
22. Gray L.H., Conger A.D., Ebert M. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:1953;638-648.
23. Krantz S.B. Erythropoietin. Blood. 77:1991;419-434.
24. Koury M.J., Bondurant M.C. The molecular mechanism of erythropoietin action. Eur J Biochem. 210:1992;649-663.
25. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 97:2000;10526-10531.
26. Marti H.H., Gassmann M., Wenger R.H., et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int. 51:1997;416-418.
27. Acs G., Acs P., Beckwith S.M., et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 61:2001;3561-3565.
28. Arcasoy M.O., Amin K., Karayal A.F., et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest. 82:2002;911-918.
29. Miller C.B., Platanias L.C., Mills S.R., et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst. 84:1992;98-103.
30. Yasuda Y., Fujita Y., Matsuo T., et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis. 24:2003;1021-1029.
31. Lutterbach J., Guttenberger R. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys. 48:2000;1345-1350.
32. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 339:1998;1506-1514.
33. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol. 15:1997;1218-1234.
34. Demetri G.D., Kris M., Wade J., Degos L., Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study: Procrit Study Group. J Clin Oncol. 16:1998;3412-3425.
35. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 19:2001;2865-2874.
36. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 4:2003;459-460.